RANTES-403 Polymorphism is Associated with Reduced Risk of Gastric Cancer in Women

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2008 Mar 1

PMID 18306985

Citations 8

Authors

Jyh-Ming Liou

Jaw-Town Lin

Shih-Pei Huang

Chun-Ying Wu

Hsiu-Po Wang

Yi-Chia Lee

Han-Mo Chiu

Chia-Tung Shun

Ming-Tsan Lin

Ming-Shiang Wu

Affiliations

Soon will be listed here.

Abstract

Background: Men are more susceptible to gastric cancer (GC) than women. However, the genetic factors associated with the sex difference are not well understood. Chemokines have been shown to modulate tumor behavior, and the sex-specific effect of the chemokine polymorphisms on the host susceptibility to several diseases has been reported. We aimed to determine the role of chemokine polymorphisms on host susceptibility to GC, with special interest on their sex-specific effect.

Methods: A hospital-based case-control study, including 177 patients with GC and 217 age-matched unaffected healthy controls, was performed in three major tertiary care hospitals. Genotyping for regulated upon activation, normal T-cell expressed and secreted (RANTES) -403 A/G and -28 C/G, CC chemokine receptor 5 (CCR5) deletion, and CCR2-V64I was performed using peripheral blood DNA.

Results: The RANTES -403 GA and AA genotypes were independently associated with a 2.3-fold reduced risk of developing GC (OR=0.44, 95% CI 0.22-0.90, P=0.025) compared with GG genotype in women, but not in men. The RANTES -28C/G and CCR2-V64I polymorphisms were not associated with different risk of developing GC. The tumor stage, histological features, and survival rate were not different when stratified by RANTES -403 and -28 and CCR2-V64I genotypes.

Conclusions: Our data indicate that women who inherit A allele at RANTES -403 may be at reduced risk of GC.

Citing Articles

The Relationship of and Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma.

Popek-Marciniec S, Styk W, Wojcierowska-Litwin M, Szudy-Szczyrek A, Dudek P, Swiderska-Kolacz G J Clin Med. 2023; 12(6).

PMID: 36983384 PMC: 10056693. DOI: 10.3390/jcm12062384.

Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer.

Mandal R, Agrawal T, Mittal R Tumour Biol. 2014; 36(1):375-81.

PMID: 25266801 DOI: 10.1007/s13277-014-2646-x.

CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects.

Ying H, Wang J, Gao X Tumour Biol. 2014; 35(6):5895-904.

PMID: 24687549 DOI: 10.1007/s13277-014-1780-9.

Differential association of RANTES-403 and IL-1B-1464 polymorphisms on histological subtypes in male Korean patients with gastric cancer.

Kim J, Kim J, Kim Y, Lee K Tumour Biol. 2013; 35(4):3765-70.

PMID: 24323564 DOI: 10.1007/s13277-013-1498-0.

Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study.

Kidd L, Jones D, Rogers E, Kidd N, Beache S, Rudd J Hered Cancer Clin Pract. 2012; 10(1):16.

PMID: 23168091 PMC: 3527309. DOI: 10.1186/1897-4287-10-16.

References

Liu H, Chao D, Nakayama E, Taguchi H, Goto M, Xin X . Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A. 1999; 96(8):4581-5. PMC: 16375. DOI: 10.1073/pnas.96.8.4581. View

Bai B, Tanaka K, Tazawa T, Yamamoto N, Sugiura H . Association between RANTES promoter polymorphism -401A and enhanced RANTES production in atopic dermatitis patients. J Dermatol Sci. 2005; 39(3):189-91. DOI: 10.1016/j.jdermsci.2005.06.003. View

Balkwill F . Cancer and the chemokine network. Nat Rev Cancer. 2004; 4(7):540-50. DOI: 10.1038/nrc1388. View

Fuchs C, Mayer R . Gastric carcinoma. N Engl J Med. 1995; 333(1):32-41. DOI: 10.1056/NEJM199507063330107. View

Kurt R, Baher A, Wisner K, Tackitt S, Urba W . Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol. 2001; 207(2):81-8. DOI: 10.1006/cimm.2000.1754. View

Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A . Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001; 7(2):285-9. View

Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H . High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol. 2004; 171(6 Pt 1):2171-5. DOI: 10.1097/01.ju.0000127726.25609.87. View

Mellado M, de Ana A, Moreno M, Martinez C, Rodriguez-Frade J . A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol. 2001; 11(9):691-6. DOI: 10.1016/s0960-9822(01)00199-3. View

Kutubuddin M, Federoff H, Halterman M, Day B, Atkinson M, Planelles V . Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood. 1999; 93(2):643-54. View

10.

Fryer A, Spiteri M, Bianco A, Hepple M, Jones P, Strange R . The -403 G-->A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun. 2001; 1(8):509-14. DOI: 10.1038/sj.gene.6363717. View

11.

Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Chaitchik S . Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999; 59(18):4681-7. View

12.

Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard R . Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res. 2007; 36(1-3):137-46. DOI: 10.1385/IR:36:1:137. View

13.

Mashino K, Sadanaga N, Tanaka F, Ohta M, Yamaguchi H, Mori M . Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol Cancer Ther. 2002; 1(10):785-94. View

14.

Nahon P, Sutton A, Rufat P, Faisant C, Simon C, Barget N . Lack of association of some chemokine system polymorphisms with the risks of death and hepatocellular carcinoma occurrence in patients with alcoholic cirrhosis: a prospective study. Eur J Gastroenterol Hepatol. 2007; 19(5):425-31. DOI: 10.1097/MEG.0b013e3280120e2b. View

15.

Petrkova J, cermakova Z, Drabek J, Lukl J, Petrek M . CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction. Immunol Lett. 2003; 88(1):53-5. DOI: 10.1016/s0165-2478(03)00053-1. View

16.

Promrat K, McDermott D, Gonzalez C, Kleiner D, Koziol D, Lessie M . Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology. 2003; 124(2):352-60. DOI: 10.1053/gast.2003.50061. View

17.

Liou J, Lin J, Wang H, Huang S, Lee Y, Shun C . The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults. Gastrointest Endosc. 2005; 61(7):819-25. DOI: 10.1016/s0016-5107(05)00366-4. View

18.

Kanda N, Watanabe S . 17beta-estradiol inhibits the production of RANTES in human keratinocytes. J Invest Dermatol. 2003; 120(3):420-7. DOI: 10.1046/j.1523-1747.2003.12067.x. View

19.

Chen Y, Vaughan R, Kondeatis E, Fortune F, Graham E, Stanford M . Chemokine gene polymorphisms associate with gender in patients with uveitis. Tissue Antigens. 2003; 63(1):41-5. DOI: 10.1111/j.1399-0039.2004.00150.x. View

20.

Mule J, Custer M, AVERBOOK B, Yang J, Weber J, Goeddel D . RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996; 7(13):1545-53. DOI: 10.1089/hum.1996.7.13-1545. View